A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent

Investigative Radiology

Volumn 48, Issue 11, 2013, Pages 745-754

  Adiseshaiah, Pavan ^a   Dellinger, Anthony ^b,c   MacFarland, Darren ^b   Stern, Stephan ^a   Dobrovolskaia, Marina ^a   Ileva, Lilia ^a   Patri, Anil K ^a   Bernardo, Marcelino ^a,d   Brooks, D Bradford ^b   Zhou, Zhiguo ^b   McNeil, Scott ^a   Kepley, Christopher ^c  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b LUNA INNOVATIONS INC   (United States)

^c Joint School of Nanoscience and Nanoengineering   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

blood compatibility; gadolinium based contrast agent; magnetic resonance imaging; nanoparticle; trimetasphere metallofullerene

Indexed keywords

COMPLEMENT; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; HYDROCHALARONE 1; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD; BLOOD CELL; BLOOD COMPATIBILITY; BLOOD SAMPLING; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DERIVATIZATION; DISPERSION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SOLUBILITY; DYNAMIC LIGHT SCATTERING; HEMOLYSIS; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STEADY STATE; THROMBOCYTE AGGREGATION;

ANIMALS; COMPLEMENT ACTIVATION; CONTRAST MEDIA; FULLERENES; GADOLINIUM; HEMOLYSIS; HUMANS; MACROMOLECULAR SUBSTANCES; MAGNETIC RESONANCE IMAGING; MICE; MICROSCOPY, ATOMIC FORCE; MOLECULAR DYNAMICS SIMULATION; NANOPARTICLES; ORGANOMETALLIC COMPOUNDS; PLATELET AGGREGATION; SPECTROPHOTOMETRY, ATOMIC;

EID: 84885420016     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318294de5d     Document Type: Article

References (73)

1. Bley TA, Wieben O, Uhl M. Diffusion-weighted MR imaging in musculo-skeletal radiology: applications in trauma, tumors, and inflammation. Magn Reson Imaging Clin N Am. 2009;17:263-275.
2. Brennan M, Spillane A, Houssami N. The role of breast MRI in clinical practice. Aust Fam Physician. 2009;38:513-519.
3. Briley-Saebo KC, Mulder WJ, Mani V, et al. Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J Magn Reson Imaging. 2007;26:460-479.
4. Deddens LH, Van Tilborg GA, Mulder WJ, et al. Imaging neuroinflammation after stroke: current status of cellular and molecular MRI strategies. Cerebrovasc Dis. 2012;33:392-402.
5. Lewis M, Yanny S, Malcolm PN. Advantages of blood pool contrast agents in MR angiography: a pictorial review. J Med Imaging Radiat Oncol. 2012;56: 187-191.
6. Quinn EM, Coveney AP, Redmond HP. Use of magnetic resonance imaging in detection of breast cancer recurrence: a systematic review. Ann Surg Oncol. 2012; 19:3035-3041.
7. Siddiki H, Fidler J. MR imaging of the small bowel in Crohn's disease. Eur J Radiol. 2009;69:409-417.
8. Soylu FN, Eggener S, Oto A. Local staging of prostate cancer with MRI. Diagn Interv Radiol. 2012;18:365-373.
9. Bumb A, Brechbiel MW, Choyke P. Macromolecular and dendrimer-based magnetic resonance contrast agents. Acta Radiol. 2010;51:751-767.
10. Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001;219:316-333.
11. Blanchette M, Pellerin M, Tremblay L, et al. Real-time monitoring of gadolinium diethylenetriamine penta-acetic acid during osmotic blood-brain barrier disruption using magnetic resonance imaging in normal Wistar rats. Neuro-surgery. 2009;65:344-350.
12. Craciunescu OI, Yoo DS, Cleland E, et al. Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra-and interpatient variability of pharmacokinetic parameters. Int J Radiat Oncol Biol Phys. 2012;82:e345-e350.
13. Jain R, Narang J, Gutierrez J, et al. Correlation of immunohistologic and perfusion vascular parameters with MR contrast enhancement using image-guided biopsy specimens in gliomas. Acad Radiol. 2011;18:955-962.
14. Percy DB, Ribot EJ, Chen Y, et al. In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol. 2011;46:718-725.
15. Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging. 2007;25:884-899.
16. Pan D, Caruthers SD, Senpan A, et al. Revisiting an old friend: manganese-based MRI contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3:162-173.
17. Sosnovik DE, Nahrendorf M, Weissleder R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation. 2007;115:2076-2086.
18. Makino A, Harada H, Okada T, et al. Effective encapsulation of a new cationic gadolinium chelate into apoferritin and its evaluation as an MRI contrast agent. Nanomedicine. 2011;7:638-646.
19. Fretellier N, Idee JM, Dencausse A, et al. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol. 2011;46:292-300.
20. Grobner T. GadoliniumVa specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
21. Langer RD, Lorke DE, Neidl van Gorkom KF, et al. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. Eur J Radiol. 2012;81:2562-2567.
22. Penfield JG, Reilly RF. Gadolinium and nephrogenic systemic fibrosis: have we overreacted? Semin Dial. 2011;24:480-486.
23. Pietsch H, Raschke M, Ellinger-Ziegelbauer H, et al. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol. 2011;46:48-56.
24. Fretellier N, Idee JM, Guerret S, et al. Clinical, biological, and skin histo-pathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol. 2011;46:85-93.
25. Feng J, Sun G, Pei F, et al. Comparison between Gd-DTPA and several bisamide derivatives as potential MRI contrast agents. Bioorg Med Chem. 2003; 11:3359-3366.
26. Riyahi-Alam N, Behrouzkia Z, Seifalian A, et al. Properties evaluation of a new MRI contrast agent based on Gd-loaded nanoparticles. Biol Trace Elem Res. 2010;137:324-334.
27. Kojima C, Turkbey B, Ogawa M, et al. Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics. Nanomedicine. 2011;7:1001-1008.
28. Luo K, Liu G, She W, et al. Gadolinium-labeled peptide dendrimers with controlled structures as potential magnetic resonance imaging contrast agents. Biomaterials. 2011;32:7951-7960.
29. Liu Y, Chen Z, Liu C, et al. Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer. Biomaterials. 2011;32:5167-5176.
30. Tian M, Wen X, Jackson EF, et al. Pharmacokinetics and magnetic resonance imaging of biodegradable macromolecular blood-pool contrast agent PG-Gd in non-human primates: a pilot study. Contrast Media Mol Imaging. 2011;6:289-297.
31. Kim JS, Rieter WJ, Taylor KM, et al. Self-assembled hybrid nanoparticles for cancer-specific multimodal imaging. J Am Chem Soc. 2007;129:8962-8963.
32. Richard C, Doan BT, Beloeil JC, et al. Noncovalent functionalization of carbon nanotubes with amphiphilic gd3+ chelates: toward powerful t1 and t2 MRI contrast agents. Nano Lett. 2008;8:232-236.
33. Chandran P, Sasidharan A, Ashokan A, et al. Highly biocompatible TiO(2):Gd(3)(+) nano-contrast agent with enhanced longitudinal relaxivity for targeted cancer imaging. Nanoscale. 2011;3:4150-4161.
34. Wen X, Jackson EF, Price RE, et al. Synthesis and characterization of poly(L-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent. Bioconjug Chem. 2004;15:1408-1415.
35. Baxter AB, Lazarus SC, Brasch RC. In vitro histamine release induced by magnetic resonance imaging and iodinated contrast media. Invest Radiol. 1993;28:308-312.
36. Mehvar R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J Control Release. 2000;69:1-25.
37. Zhang Z, Nair SA, McMurry TJ. Gadolinium meets medicinal chemistry: MRI contrast agent development. Curr Med Chem. 2005;12:751-778.
38. Fatouros PP, Corwin FD, Chen ZJ, et al. In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle. Radiology. 2006;240:756-764.
39. Fillmore HL, Shultz MD, Henderson SC, et al. Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors. Nanomedicine (Lond). 2011;6:449-458.
40. MacFarland DK, Walker KL, Lenk RP, et al. Hydrochalarones: a novel endo-hedral metallofullerene platform for enhancing magnetic resonance imaging contrast. J Med Chem. 2008;51:3681-3683.
41. Stevenson S, Fowler PW, Heine T, et al. A stable non-classical metallofullerene family. Nature. 2000;408:427-428.
42. Zhou G, Li Y, Liu Y, et al. Subcellular distribution of polyhydroxylated metallofullerene Gd@C82(OH)22 in different tissues of tumor-bearing mice. J Nanosci Nanotechnol. 2010;10:8597-8602.
43. Meng J, Wang DL, Wang PC, et al. Biomedical activities of endohedral metal-lofullerene optimized for nanopharmaceutics. J Nanosci Nanotechnol. 2010; 10:8610-8616.
44. Bolskar RD. Gadofullerene MRI contrast agents. Nanomedicine (Lond). 2008; 3:201-213.
45. Runge VM. Gadolinium and nephrogenic systemic fibrosis. AJR Am J Roentgenol. 2009;192:W195-W196.
46. Dunsch L, Yang S. Metal nitride cluster fullerenes: their current state and future prospects. Small. 2007;3:1298-1320.
47. Dunsch L, Yang S. Endohedral clusterfullerenesVplaying with cluster and cage sizes. Phys Chem Chem Phys. 2007;9:3067-3081.
48. TM (Endohedral Mettalo-fullerenes). US Radiology. 2011;1:84-86.
49. Neun BW, Dobrovolskaia MA. Detection .and quantitative evaluation of en-dotoxin contamination in nanoparticle formulations by LAL-based assays. In: McNeil S, ed. Characterization of Nanoparticles Intended for Drug Delivery. New York, NY: Humana Press; 2011:121-130.
50. Neun BW, Dobrovolskaia MA. Method for analysis of nanoparticle hemo-lytic properties in vitro. In: McNeil S, ed. Characterization of Nanoparticles Intended for Drug Delivery. New York, NY: Humana Press; 2011:215-224.
51. Neun BW, Dobrovolskaia MA. Method for in vitro analysis of nanoparticle thrombogenic properties. In: McNeil S, ed. Characterization of Nanoparticles Intended for Drug Delivery. New York, NY: Humana Press; 2011:225-235.
52. Neun BW, Dobrovolskaia MA. Qualitative analysis of total complement activation by nanoparticles. In: McNeil S, ed. Characterization of Nanoparticles Intended for Drug Delivery. New York, NY: Humana Press; 2011;237-245.
53. Standard Procedure G859 Bacterial Endotoxins Test. Rockville, MD: The United States Pharmacopeial Convention; 2007: 109-113.
54. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.
55. Yang D, Zhao Y, Guo H, et al. [Gd@C(82)(OH)(22)](n) nanoparticles induce dendritic cell maturation and activate Th1 immune responses. ACS Nano. 2010;4:1178-1186.
56. Meng J, Xing J, Wang Y, et al. Epigenetic modulation of human breast cancer by metallofullerenol nanoparticles: in vivo treatment and in vitro analysis. Nanoscale. 2011;3:4713-4719.
57. Liang XJ, Meng H, Wang Y, et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A. 2010;107:7449-7454.
58. Han L, Li J, Huang S, et al. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials. 2011;32:2989-2998.
59. Muhler A, Clement O, Saeed M, et al. Gadolinium-ethoxybenzyl-DTPA, a new liver-directed magnetic resonance contrast agent. Absence of acute hepatotoxic, cardiovascular, or immunogenic effects. Invest Radiol. 1993;28:26-32.
60. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216:106-121.
61. Pham CT, Mitchell LM, Huang JL, et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem. 2011;286:123-130.
62. Bolskar RD, Benedetto AF, Husebo LO, et al. First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C60[C(COOH)2]10 as a MRI contrast agent. J Am Chem Soc. 2003;125: 5471-5478.
63. Mikawa M, Kato H, Okumura M, et al. Paramagnetic water-soluble metal-lofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem. 2001;12:510-514.
64. Zhang J, Fatouros PP, Shu C, et al. High relaxivity trimetallic nitride (Gd3N) metallofullerene MRI contrast agents with optimized functionality. Bioconjug Chem. 2010;21:610-615.
65. Eldredge HB, Spiller M, Chasse JM, et al. Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest Radiol. 2006;41:229-243.
66. Gilbert FJ, Ahearn TS. Dynamic contrast-enhanced MRI in cancer. Imaging Med. 2009;1:173-186.
67. Laurent S, Burtea C, Vander Elst L, et al. Synthesis and characterization of new low-molecular-weight lysine-conjugated Gd-DTPA contrast agents. Contrast Media Mol Imaging. 2011;6:229-235.
68. Unger EC, MacDougall P, Cullis P, et al. Liposomal Gd-DTPA: effect of encapsulation on enhancement of hepatoma model by MRI. Magn Reson Imaging. 1989;7:417-423.
69. Xing G, Yuan H, He R, et al. The strong MRI relaxivity of paramagnetic nanoparticles. J Phys Chem B. 2008;112:6288-6291.
70. Dellinger A, Zhou Z, Norton SK, et al. Uptake and distribution of fullerenes in human mast cells. Nanomedicine. 2010;6:575-582.
71. Norton SK, Dellinger A, Zhou Z, et al. A new class of human mast cell and peripheral blood basophil stabilizers that differentially control allergic mediator release. Clin Transl Sci. 2010;3:158-169.
72. Ryan JJ, Bateman HR, Stover A, et al. Fullerene nanomaterials inhibit the allergic response. J Immunol. 2007;179:665-672.
73. Zhou Z, Lenk R, Dellinger A, et al. Fullerene nanomaterials potentiate hair growth. Nanomedicine. 2009;5:202-207.